PROPOSED, not final. Not FDA approval.

HHS's 503A peptide proposal, explained

Status: PROPOSED, not final. This is a draft HHS policy open for public comment. It is not FDA approval of any peptide, and it does not make these peptides FDA-approved drugs. Education only, not medical advice. No dosing information.

What was proposed

  • HHS published a notice about a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (Docket HHS-OASH-2026-0496). Federal Register 2026-22192 · public inspection PDF
  • Under the draft, HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians compounding with the listed peptides, if strict conditions are met, while FDA develops the official 503A bulks list through rulemaking. FR 2026-22192
  • Conditions in the draft include: the exact peptide identity HHS specifies, ingredients from an FDA-registered manufacturer with a valid certificate of analysis (testing for identity, purity, potency and contaminants), single-ingredient products, reporting of serious adverse events to FDA's MedWatch, "compounded drug product, not for resale" labeling, and a valid patient-specific prescription. HHS policy PDF
  • HHS says the aim is to discourage widespread use of "research-use-only" peptides from foreign suppliers that pose safety risks. HHS policy PDF

Which peptides are named

The Federal Register notice refers to the peptides only as "Appendix A" and doesn't list them in its text. Read the list in the policy document on the regulations.gov docket.

What it means for you, in plain words

  • Nothing is final yet. It is a draft, open for comment, and HHS states it "does not establish any rights for any person and is not binding." FR 2026-22192
  • Not FDA approval. HHS notes compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing. FR 2026-22192
  • Prescription-based, pharmacy-based. The draft concerns licensed pharmacies and physicians compounding for an individual patient with a prescription, not over-the-counter or "research" sellers. HHS policy PDF
  • It can change. HHS says it may revisit the policy if a safety signal or quality issue arises, and FDA's future rulemaking may or may not add these peptides to the 503A bulks list. FR 2026-22192
  • Talk to a licensed clinician before making any health decision.

Status and next steps

  • Filed: Oct 28, 2026, for public inspection. Scheduled publication: Oct 30, 2026. FR 2026-22192
  • Comment period: written comments accepted "until 2 weeks after date of publication" via regulations.gov, Docket HHS-OASH-2026-0496. The Federal Register lists Oct 30, 2026 as the publication date, so comments close about Nov 13, 2026; check the docket for the exact closing time. FR 2026-22192
  • Next: HHS reviews comments; FDA rulemaking on the 503A bulks list continues. We will update this page when anything changes.

See where each peptide stands

Track peptides alongside research-only, investigational and FDA-approved peptides on Peptide Horizon →.

FAQ

Did HHS approve the peptides in the proposal? No. This is a draft enforcement discretion policy, not FDA approval, and it is not final. FR 2026-22192

Which peptides are in the proposal? The Federal Register notice refers to the peptides only as "Appendix A" and doesn't list them in its text. Read the list in the policy document on the regulations.gov docket.

What is 503A compounding? Section 503A of the FD&C Act covers licensed pharmacists or physicians preparing a medication tailored to an individual patient, based on a prescription. Compounded drugs are not FDA-approved. FR 2026-22192

When is the comment deadline? Two weeks after Federal Register publication on Oct 30, 2026, so about Nov 13, 2026. Check the regulations.gov docket for the exact closing time. FR 2026-22192

How can I comment? Through regulations.gov, Docket HHS-OASH-2026-0496. FR 2026-22192

Does this cover "research-use-only" peptides sold online? No. HHS says the policy aims to discourage use of research-use-only peptides from foreign suppliers. HHS policy PDF

Alerts